Mekinist
Mekinist is the brand name for trametinib, a targeted cancer therapy that inhibits MEK1 and MEK2 kinases in the MAPK/ERK signaling pathway. By blocking MEK activity, trametinib can reduce proliferation and survival of tumor cells driven by MAPK pathway activation. Mekinist is developed by Novartis.
In the United States and European Union, Mekinist is approved for the treatment of unresectable or metastatic
Trametinib is taken orally, usually once daily, with dosing adjusted for tolerability and patient factors. It
Common adverse effects include rash, diarrhea, edema, fatigue, and nausea. Ocular toxicity requiring monitoring, including retinal
Beyond melanoma, trametinib has been studied in other MAPK-activated tumors and in combination regimens, contributing to